as 01-17-2025 4:00pm EST
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
Founded: | 2015 | Country: | United States |
Employees: | N/A | City: | WILMINGTON |
Market Cap: | 14.8M | IPO Year: | N/A |
Target Price: | $31.67 | AVG Volume (30 days): | 2.8M |
Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -2.12 | EPS Growth: | N/A |
52 Week Low/High: | $1.10 - $7.33 | Next Earning Date: | 11-14-2024 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
NRXP Breaking Stock News: Dive into NRXP Ticker-Specific Updates for Smart Investing
PR Newswire
5 days ago
PR Newswire
6 days ago
PR Newswire
9 days ago
PR Newswire
12 days ago
PR Newswire
13 days ago
PR Newswire
13 days ago
PR Newswire
16 days ago
PR Newswire
17 days ago
The information presented on this page, "NRXP NRX Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.